Eyestem presents interim Phase 2 Eyecyte-RPE data at EURetina 2026
In short
Eyestem Research presented interim Phase 2 results for Eyecyte-RPE™ at the EURetina 2026 Conference. The trial is for Geographic Atrophy linked to dry age-related macular degeneration.
The report does not share the data details or say what comes next. So the effect on the treatment and the company is still unknown.
What the reporting says
Eyestem Research presented interim results from its Phase 2 clinical trial of Eyecyte-RPE™ at the EURetina 2026 Conference. The trial focuses on Geographic Atrophy secondary to dry age-related macular degeneration. The reporting does not include the trial results themselves or whether the data changed the company’s next steps.
Why it matters
Eyestem Research used the EURetina 2026 Conference to present interim Phase 2 data for Eyecyte-RPE™, a treatment being studied for Geographic Atrophy secondary to dry age-related macular degeneration. This is a clinical-stage update for the company and the eye-disease area, but the source does not disclose the actual results, safety findings, or development timeline. The market impact is therefore uncertain.